4.7 Article

Anatomic Versus Physiologic Assessment of Coronary Artery Disease

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 62, 期 18, 页码 1639-1653

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2013.07.076

关键词

coronary flow; coronary physiology; ischemia; PET perfusion imaging; revascularization

资金

  1. Weatherhead PET Center for Preventing and Reversing Atherosclerosis
  2. Bracco
  3. Philips
  4. GE
  5. SpectrumDynamics
  6. Astellas
  7. Heart and Stroke Foundation of Ontario
  8. GE Healthcare
  9. Nordion
  10. Lantheus Medical Imaging
  11. DRAXImage
  12. Genentech
  13. Bracco Diagnostics
  14. Perceptive Informatics
  15. Toshiba Medical Systems
  16. Gilead
  17. Astellas Pharma
  18. Wild Family Foundation
  19. FluoroPharma, Inc.
  20. NIH
  21. Swiss National Science Foundation
  22. Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
  23. Academy of Finland Centre of Excellence in Molecular Imaging in Cardiovascular and Metabolic Research, Helsinki, Finland
  24. Gilead Inc.
  25. MDS Nordion
  26. Siemens
  27. Lantheus
  28. Molecular Insight Pharmaceuticals
  29. Philips Healthcare

向作者/读者索取更多资源

Angiographic severity of coronary artery stenosis has historically been the primary guide to revascularization or medical management of coronary artery disease. However, physiologic severity defined by coronary pressure and/ or flow has resurged into clinical prominence as a potential, fundamental change from anatomically to physiologically guided management. This review addresses clinical coronary physiology-pressure and flowd-as clinical tools for treating patients. We clarify the basic concepts that hold true for whatever technology measures coronary physiology directly and reliably, here focusing on positron emission tomography and its interplay with intracoronary measurements.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据